A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol

Background: Chemotherapy combined with antivascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor monoclonal antibodies is the most promising approach to prolong survival and improve the quality of life of patients with unresectable metastatic colorectal cancer (mCRC). An...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Jinjie, Liu, Yue, Liu, Chengcheng, Hu, Hanguang, Sun, Lifeng, Xu, Dong, Li, Jun, Wang, Junye, Chen, Xiaobing, Lin, Rongbo, Jiang, Yi, Zhang, Yanqiao, Zhang, Weisheng, Cheng, Ying, Wu, Xiaohong, Fang, Mingzhi, Li, Enxiao, Xu, Ye, Chen, Ye, Li, Jiayi, Cui, Yanyan, Pan, Zhanyu, Zhang, Songnan, Yuan, Ying, Ding, Kefeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900663/
https://www.ncbi.nlm.nih.gov/pubmed/36727222
http://dx.doi.org/10.1177/15330338231152350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900663/
https://www.ncbi.nlm.nih.gov/pubmed/36727222
http://dx.doi.org/10.1177/15330338231152350

Ejemplares similares